Literature DB >> 2060528

Long-term follow-up of patients with AIDS on maintenance therapy for toxoplasmosis.

C Leport1, C Tournerie, G Raguin, J Fernandez-Martin, T Niyongabo, J L Vildé.   

Abstract

To assess potential interactions of multiple drug regimens administered to patients with AIDS for toxicity and efficacy, we reviewed the charts of 35 patients on maintenance therapy for toxoplasmosis. Seven relapses of toxoplasmosis occurred in 6 of 35 (17%) patients, and seven episodes of pneumocystosis occurred in 6 of 35 (17%) patients. Four relapses of toxoplasmosis and 5 relapses of pneumocystosis were seen in 20 patients treated with pyrimethamine/clindamycin; 2 relapses of toxoplasmosis and 2 relapses of pneumocystosis were seen in 11 patients treated with pyrimethamine alone, and 1 relapse of toxoplasmosis was seen in 13 patients treated with pyrimethamine/sulfadiazine. Adverse effects were related to pyrimethamine in 10 patients, to clindamycin in 7 patients, and to sulfadiazine in 8 patients. These results must be compared with those of prospective trials to determine the efficacy and safety of various maintenance regimens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060528     DOI: 10.1007/bf01964460

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  3 in total

1.  Failure of pyrimethamine-clindamycin combination for prophylaxis of Pneumocystis carinii pneumonia.

Authors:  P M Girard; A Lepretre; P Detruchis; S Matheron; J P Coulaud
Journal:  Lancet       Date:  1989-06-24       Impact factor: 79.321

2.  Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy.

Authors:  C Leport; F Raffi; S Matheron; C Katlama; B Regnier; A G Saimot; C Marche; C Vedrenne; J L Vilde
Journal:  Am J Med       Date:  1988-01       Impact factor: 4.965

Review 3.  NIH conference. Pneumocystis pneumonia: from bench to clinic.

Authors:  H Masur; H C Lane; J A Kovacs; C J Allegra; J C Edman
Journal:  Ann Intern Med       Date:  1989-11-15       Impact factor: 25.391

  3 in total
  4 in total

Review 1.  Drug treatment of HIV-related opportunistic infections.

Authors:  M E Klepser; T B Klepser
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

2.  Efficacy of pyrimethamine/sulfadoxine in the prevention of toxoplasmic encephalitis relapses and Pneumocystis carinii pneumonia in HIV-infected patients.

Authors:  B Ruf; D Schürmann; F Bergmann; W Schüler-Maué; T Grünewald; H J Gottschalk; H Witt; H D Pohle
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

Review 3.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

Review 4.  Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis.

Authors:  Mark P Connolly; Elizabeth Goodwin; Carina Schey; Jacqueline Zummo
Journal:  Pathog Glob Health       Date:  2017-01-16       Impact factor: 2.894

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.